Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can your own stem cells repair heart attack damage?

NCT ID NCT01652209

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether injecting a patient's own bone marrow stem cells into the heart's arteries could improve heart function after a heart attack. 90 adults with reduced heart pumping ability were randomly assigned to receive either stem cells plus standard care or standard care alone. The main goal was to see if the stem cell group had better heart function after 13 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autologous bone marrow derived mesenchymal stem cells (Hearticellgram-AMI)
What this could lead to
If successful, this could provide a way to improve heart function and reduce damage after a heart attack, potentially lowering the risk of heart failure.
What could go wrong
This trial is completed but results are not yet widely confirmed. Stem cell therapies can have variable effects, and benefits may be modest or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

90 people

The number who actually took part.

Started

Sep 2013

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. As of the date of written consent, between 20 and 75 years of age 2. Those with less than 50% of the left ventricular ejection fraction (LVEF) on echocardiography performed after percutaneous coronary intervention (PCI) (evaluated by investigator) 3. Who has been identified as an acute myocardial infarction in any of the following on an electrocardiogram (12-lead electrocardiography, ECG) performed before PCI * ST-segment elevation 0.1 mV in two or more limb leads or * 0.2 mV elevation in two or more contiguous precordial leads indicative of acute myocardial infarction (AMI) 4. Those identified as anterior wall MI 5. Who meet the above criteria and have successfully reperfused within 72 hours after the onset of chest pain 6. Who can conduct clinical trials according to the clinical trial protocol 7. Who has consented in writing to voluntarily participate in this clinical trial (owner or legal representative) Exclusion Criteria: 1. Who have not been diagnosed with malignant blood diseases (acute myelogenous leukemia, acute lymphocytic leukemia, non-Hodgkins lymphoma, Hodgkins lymphoma, multiple myelopathy) within 5 years of screening criteria 2. Patients with severe aplastic anemia 3. Patients with solid cancers in their previous medical history (within 5 years) 4. Patients whose blood serum AST/ASL rates are more than three times the normal maximum rate, and whose creatinine rates are more than 1.5 times the normal maximum rate (but AST in myocardial infarction patients can temporarily rise, thus, as decided by the researchers, if there is no damage to the liver function, the rise will not be taken into consideration) 5. Patients who have implemented Coronary Artery Bypass Graft(CABG) 6. Patients with chronic heart failure (patients with medical history of heart failure medical history at least three months before the occurrence of acute myocardial infarction) 7. Patients who cannot proceed with cardiac catheterization 8. Patients who had been continuously taking large doses of steroids (1mg/kg/day) or antibiotics for severe infections from one month prior to registration 9. Patients who had major surgical operations, organ biopsy, or significant external injury as determined by the researcher, within three months before registration 10. Patients who have head injuries or other external injuries after the development of myocardial infarction 11. patients with stroke or transient ischemic attack within six months before registration, patients with history of central nervous system disease (tumor, aneurysm, brain surgery etc.) 12. Patients with low survival ability after cardiopulmonary resuscitation within last 2 weeks. 13. Patients with positive for HIV, HBV, HCV, Syphilis 14. pregnant women or likely to be pregnant or lactating women 15. Patients with drug abuser within last 1 year. 16. Patients with participating other clinical trials with last 1 month. 17. When the possibility of tumor occurrence is seen when the tester judges even one of the tumor marker tests during screening 18. Who are judged to be inappropriate to participate in this test when judged by the examiner

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Catholic University of Korea, Seoul ST. Mary's Hospital.

    Seoul, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Chungnam National University Hospital

    Jungnam, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Kangwon National University Hospital

    Chuncheon, South Korea

  • Korea University Medicine

    Seoul, South Korea

  • Severance Hospital, Yonsei University College of Medicine

    Seoul, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, South Korea

  • Yongin Severance Hospital

    Gyeonggi-do, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.